EHA 2026 | DREAMM-9 final analysis: Bela-VRd shows deep responses in transplant-ineligible myeloma

We will present this data as in all our presentations here at EHA. And it is, you know that, well, now treatment of multiple myeloma and newly diagnosed myeloma has really been an explosion of new drugs and particularly of new combinations. The quadruplets have revolutionized this treatment and also in the non-transplant candidates. This now here in this study, this is a Phase Ib study, the DREAMM-9, that would evaluate quadruplet combination, substituting the anti-CD38 monoclonal antibody with belantamab mafodotin with the antibody-drug conjugate. So this is Bela-VRd for these non-transplant candidate patients. Phase 1 study, multi-cohort study. And while we have 118 patients included in different cohorts, as I said, with different starting doses of belantamab mafodotin , 1.9, 1.4 on one. And what is more important is different schedules of treatment of belantamab. Belantamab is given in some cohorts, once in every cycle. In the other cohort, it is given once every two cycles. And the other one is once every three cycles. So, induction and then also in maintenance. And what we see in these patients with a median age of 74 years is that they have very good responses, with 90% responses, with more than 50% MRD negativity rate, particularly maybe in those that receive the drug every six or eight weeks, so that is every two cycles, they have one dose of belantamab, and I think this is very interesting because we have this efficacy. Also, what is very important, the primary endpoint of the trial was safety; we know and it was published and presented previously that it’s very well tolerated and here we will also focus on the corneal toxicity and what we see is the corneal events are really reduced when we skip some doses of belantamab and we’ll be fit in the induction probably every two cycles, every six weeks. And then in the maintenance phase, which is from cycle nine and on, we give belantamab every three cycles. Here we see that we keep the doses, the cumulative doses of belantamab maintained also, and we decrease really the dose or the incidence of the corneal adverse events. So I think this is interesting to have this combination with Bela and the starting point for newer combinations or newer studies evaluating this drug in this newly diagnosed setting.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.